CD8A and neoplasm: Recently, new radiotracers have been developed to monitor the distribution of tumor biomarkers in vivo [39] [40], and a phase I study has been conducted to perform CD8 PET imaging of TILs with a radiolabeled anti-CD8 minibody [41].